Search Results

Deals

Polyphor Closes Merger with EnBiotix and is Renamed Spexis

Polyphor AG and EnBiotix Inc. announced the closing of the merger of the two companies and the change of name of the combined company to Spexis AG.

December 30, 2021

·

4 min read

Polyphor to Inform about the Financing of its Merger Partner EnBiotix

Polyphor AG and EnBiotix Inc. announced that EnBiotix has completed a convertible debenture raise of USD 11 million to finance its future operations.

December 29, 2021

·

2 min read

Deals

Polyphor and EnBiotix Announce Signing of Merger Agreement and Sale of Inhaled Murepavadin to EnBiotix

Polyphor and EnBiotix Inc. announced that the companies have signed a merger agreement pursuant to which Polyphor acquires all of the outstanding capital stock of EnBiotix in exchange for shares of Polyphor common stock.

September 1, 2021

·

7 min read

Polyphor Shareholders Approve All Resolutions for the Planned Merger with EnBiotix at the Extraordinary General Meeting

Polyphor AG announced that its shareholders approved all proposals of the Board of Directors at the Extraordinary General Meeting on October 28, 2021, with a significant majority.

October 29, 2021

·

3 min read

Drug Development

Polyphor and EnBiotix Announce Dosing of First Patient in a First-in-Human Clinical Trial of Inhaled Murepavadin

Polyphor AG and EnBiotix Inc. announced that the first subjects have been dosed in the first-in-human Phase I trial of a novel-class antibiotic murepavadin, delivered via the oral inhalation route.

December 15, 2021

·

3 min read

Polyphor Publishes Invitation to Extraordinary General Meeting and Announces Financial Results for the First Half 2021

Polyphor AG published the invitation to its Extraordinary General Meeting on October 28, 2021 and announced financial results for the first half of 2021.

September 27, 2021

·

5 min read

Polyphor to Present at the UBS Global Healthcare Virtual Conference

Polyphor AG a research driven clinical stage, Swiss biopharmaceutical company committed to discovering and developing best-in-class molecules in oncology and antimicrobial resistance announced that the company will present at the UBS Global Healthcare Virtual Conference, taking place May 24 -26, 2021.

May 18, 2021

·

2 min read

Deals

Polyphor to Present Full-Year 2020 Financial Results on March 5

Polyphor AG announced that it will publish its full-year financial results for 2020 on March 5 at 7:30am CET.

February 26, 2021

·

2 min read

Drug Development

Polyphor Provides Update on the Phase III FORTRESS Study of Balixafortide in Patients With Advanced HER2 Negative Breast Cancer

Polyphor AG announced that its global Phase III study, FORTRESS, evaluating balixafortide in combination with eribulin for the treatment of patients with HER2 negative, locally recurrent or metastatic breast cancer, did not meet its co-primary endpoint.

June 28, 2021

·

4 min read

Drug Development

Polyphor completes recruitment in Phase III trial of balixafortide in metastatic breast cancer

Polyphor AG announces that it has completed recruitment in its FORTRESS Phase III study of balixafortide in metastatic breast cancer.

October 29, 2020

·

3 min read